TUDCA and UDCA are chemically related bile acids with overlapping but distinct pharmacological profiles. Understanding the differences is essential for informed clinical decisions, supplement selection, and procurement. This article provides a rigorous, evidence-based comparison.
TUDCA is the taurine conjugate of UDCA. UDCA is ursodeoxycholic acid (molecular formula C24H40O4, molecular weight 392.57). TUDCA is formed when a taurine molecule (NH2CH2CH2SO3H) is conjugated to the carboxyl group of UDCA via an amide bond, yielding a molecule with formula C26H45NO6S and molecular weight 499.7. The taurine conjugation adds a sulfonic acid group that is fully ionized at physiological pH, making TUDCA a stronger acid (lower pKa) than UDCA. This results in higher aqueous solubility and resistance to passive reabsorption in the biliary tree, both of which contribute to more efficient enterohepatic recycling and higher steady-state bile concentrations.
Pharmacologically, the two compounds share core mechanisms: both are hydrophilic bile acids that enrich the bile acid pool at the expense of toxic hydrophobic species, both inhibit hepatocyte apoptosis via the mitochondrial pathway, and both stimulate bile flow. The differences emerge in three areas: (1) TUDCA has independently documented chemical chaperone activity (reducing ER stress) that is not a well-characterized property of unconjugated UDCA, (2) TUDCA crosses the blood-brain barrier while UDCA does so minimally, and (3) TUDCA activates the PI3K/Akt survival pathway more potently than UDCA in direct comparison studies.
UDCA (ursodiol): FDA-approved as a prescription drug under the brand names Actigall and Urso. Approved indications are (a) dissolution of radiolucent, non-calcified gallbladder stones <20 mm in diameter in patients who are candidates for elective cholecystectomy (8–10 mg/kg/day), and (b) treatment of primary biliary cholangitis (13–15 mg/kg/day). Generic UDCA has been available since the early 2000s. The drug is also approved in the EU, Japan, and most regulated pharmaceutical markets worldwide for these indications. UDCA is additionally authorized in the EU for intrahepatic cholestasis of pregnancy and pediatric cholestatic disorders.
TUDCA: Not FDA-approved for any indication. It is sold as a dietary supplement in the United States under DSHEA (Dietary Supplement Health and Education Act of 1994). As a supplement, it falls outside FDA pre-market approval, and manufacturers are responsible for ensuring that labeling is truthful and not misleading. No new dietary ingredient (NDI) notification for TUDCA has been publicly acknowledged by the FDA. In the EU, TUDCA's regulatory classification varies by member state; it is generally sold as a food supplement, but some jurisdictions may classify it differently based on local interpretation of the food-medicine boundary.
Oral bioavailability of both compounds is limited by intestinal absorption and first-pass hepatic extraction. UDCA oral bioavailability is approximately 30–60% of the administered dose (variable, reduced by food and gastric pH). TUDCA bioavailability data are limited by fewer published studies, but the taurine conjugate's higher water solubility predicts more consistent dissolution-limited absorption. In bile fistula models, TUDCA's biliary recovery (a measure of enterohepatic cycling) exceeds that of UDCA at equimolar doses, consistent with higher bioavailability.
The blood-brain barrier penetration of TUDCA is a key differentiator. In rodent models, TUDCA concentrations in brain tissue, measured by LC-MS/MS, are 5–10 times higher than UDCA concentrations after equimolar oral dosing. The mechanism involves active transport across brain capillary endothelial cells, likely via the apical sodium-dependent bile acid transporter (ASBT/SLC10A2) expressed at the blood-brain barrier in some species. UDCA, lacking the taurine conjugate, is a poor substrate for ASBT-mediated transport. This pharmacokinetic difference explains why TUDCA, but not UDCA, has been investigated for neurological indications.
| Evidence Parameter | TUDCA | UDCA |
|---|---|---|
| Phase III RCTs completed | 1 (ALS, 2024 — negative) | >15 (PBC, gallstones, ICP) |
| Total published human subjects | <200 | >10,000 |
| Guideline inclusion | None | EASL, AASLD, ACG, ACOG, RCOG, ESPGHAN |
| Longest RCT duration | 54 weeks | >10 years (PBC extension studies) |
| Meta-analyses available | 0 | Multiple (Cochrane, specialty journals) |
| Neurological evidence | Preclinical; 1 positive ALS pilot, 1 negative Phase 3; 1 Phase 1/2 MS safety trial | None |
UDCA has overwhelmingly more clinical evidence than TUDCA and is the clear choice for any indication where UDCA has proven efficacy (PBC, gallstones, ICP). TUDCA's evidence advantage is solely in neurological conditions where UDCA is ineffective due to its inability to cross the blood-brain barrier.
UDCA as a generic prescription drug costs approximately $3–$8/day at standard PBC doses (1,000–1,500 mg/day for a 70 kg patient). Brand-name Actigall or Urso is $15–$30/day. Insurance typically covers FDA-approved indications. TUDCA as an OTC supplement costs approximately $0.50–$2.00/day at standard supplement doses (250–500 mg/day) and $2–$5/day at higher neurological protocol doses (1,000–1,500 mg/day). No insurance coverage. For a patient with an FDA-approved indication, prescription UDCA may actually be cheaper than OTC TUDCA after insurance, despite the higher nominal per-milligram cost of the pharmaceutical.
| Scenario | Recommended Choice | Rationale |
|---|---|---|
| PBC diagnosis | UDCA (prescription) | FDA-approved; guideline-recommended; multiple phase III trials |
| Gallstone dissolution | UDCA (prescription) | FDA-approved; established efficacy criteria |
| ICP (pregnancy) | UDCA (prescription) | ACOG/RCOG recommended; PITCHES trial data |
| General liver support (OTC) | TUDCA or UDCA | Comparable hepatoprotection; TUDCA has additional mechanisms |
| Neurological interest (off-label) | TUDCA (supplement) | UDCA does not cross BBB; preclinical TUDCA neuroprotection data |
| Cost-sensitive with insurance | UDCA (prescription) | May be lower out-of-pocket cost after insurance |
| No insurance coverage | TUDCA (supplement) | Lower absolute cost; available without prescription |